Co-encapsulation by Flash NanoPrecipitation of Insulin, Trypsin Inhibitor and Caprate Permeabilization Enhancer for Oral Administration

Simon A. McManus†, Yingyue Zhang†, Bumjun Kim1, Byung Kook Lee2, Mohamed E.H. ElSayed2*, Robert K. Prud’homme1*

1. Department of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey 08544, United States
2. Biotechnology Discovery Research, Eli Lilly and Company, Lilly Technology Center North Indianapolis, Indiana 46221, United States

Graphical Abstract

Abstract

We describe inverse-Flash NanoPrecipitation (iFNP) as a new scalable platform for co-encapsulation of insulin (model therapeutic peptide) with soybean trypsin inhibitor (SBTI, peptidase inhibitor) and sodium caprate (C10, permeation enhancer) forming 300 nm particles for oral delivery. The co-encapsulation of the protein therapeutic with a protease inhibitor and a permeation enhancer into nanoparticle form addresses enzymatic attack on the protein drug and the transport across the gastrointestinal tract (GIT) barrier. iFNP encompasses two sequential precipitation processes with insulin, SBTI, and a stabilizing block copolymer at mass ratios of 1:4:5 rapidly precipitated into an organic antisolvent forming the inverted nano-core (iNC) with 50 wt% insulin and SBTI and encapsulation efficiencies greater than 98%. The second step involves the precipitation of sodium caprate and a stabilizing polymer coating onto the iNCs surface. HPMCAS, chitosan, and PEG polymers were used to coat the iNCs to generate nanoparticles (NPs) with anionic, cationic, and neutral surfaces, respectively. This demonstrates that the iFNP platform encapsulates complex biologics mixtures at high loadings into particles with customizable surface properties.

Keywords:
Nano-encapsulation, oral delivery, soybean trypsin inhibitor, caprate, permeabilization enhancer, insulin, protein, nanocarrier, nanoparticle

* Robert K. Prud’homme, Dept. Chem. and Biol. Engr., Princeton University, Princeton, NJ 08544, Email: prudhomm@princeton.edu, Phone: 609 258 4577, and Mohamed E.H. ElSayed, Ph.D.E-mail: Mohamed.elsayed@lilly.com, Phone: +1 317-277-4696
Rationale and Purpose

Peptide and protein therapeutics are the fastest-growing segments of the pharmaceutical market. Their greater specificity and lower non-specific toxicity compared with small molecule drugs have driven this growth.[1, 2] However, the greatest challenge in the field is delivery. Although there have been significant advances, oral delivery is still a mostly unrealized opportunity.[3] Complex processing strategies for encapsulation and limitations on the biologic loading and loading efficiency have slowed clinical translation. Typical liposome loadings are at most 10%, while polymeric nanocarriers are frequently 2 wt% or less. [4-12]

Introduction

We present a new encapsulation approach that addresses these limitations. The technique termed inverse-Flash NanoPrecipitation (iFNP) is a two-step encapsulation process wherein the soluble biologic is first precipitates as a block-copolymer protected nanoparticle into a non-aqueous phase. Subsequently, a second coating step provides a biocompatible coating layer. Figure 1 shows the concept map for the nanocarrier constructs that can be prepared by iFNP.

Figure 1. Concept map of nanocarrier (NC) delivery of insulin. The schematic shows the two concepts. A) NCs may be muco-adhesive or muco-diffusive. B) NCs may release an enzyme inhibitor (SBTI) to prevent protein degradation, and the protein, or the NCs may release an enzyme inhibitor; the protein, and a permeabilization enhancer to increase delivery effectiveness.

The first step creates highly loaded cores (50 wt% biologic) at 95% encapsulation efficiency. In the second coating step, neutral (PEG), anionic or cationic coatings are assembled on the nanoparticle surface. Both steps involve a continuous, block-copolymer-directed, kinetically controlled precipitation under turbulent flow in specially designed mixing chambers. [13-15] The block-copolymer precipitation process is scalable – the same 100 nm nanoparticles have been demonstrated using 1 mg of sample and at 10 L/minute to make 300 L batches [16]. The previous examples of the iFNP process [12, 17, 18] have been directed to parenteral administration and do not present the challenges associated with oral protein delivery. To address oral delivery, the peptides/proteins are formulated with peptidase inhibitors to minimize the degradative effect of GIT enzymes and permeation enhancers to increase peptide's diffusion across the mucosal barrier. There is debate about whether oral delivery of nanoparticles is best achieved when the nanoparticles' surfaces are mucoadhesive [19, 20] or when
they are neutral (PEG) and mucodiffusive. [21, 22] Therefore, to demonstrate the iFNP platform's flexibility, we prepare nanoparticles with highly cationic, anionic, and neutral surfaces. The nanocarriers (NCs) can be prepared with surface coatings to make them mucoadhesive or mucodiffusive, and the NCs can encapsulate insulin, a protease inhibitor (SBTI), and a permeabilization enhancer (sodium caprate).

**Materials and Methods**

**Experimental Design**

The goal of this proof-of-concept study was to evaluate the ability of the iFNP process as a robust and scalable platform for encapsulation of complex mixtures of therapeutic peptides and functional excipients into nanoparticles (NPs) with tunable surface charge to facilitate specific interactions with the mucus lining of the intestinal tract. Insulin was chosen as the model peptide, while soybean trypsin inhibitor (SBTI, 21 kDa) was used as a peptidase inhibitor to minimize insulin degradation in the GI tract, and sodium caprate (C10) was chosen as a permeation enhancer. The first step of iFNP involved the precipitation of insulin and SBTI. For this model study, a non-degradable polystyrene-b-polyacrylic acid (PS-b-PAA) polymer was used as stabilizing the stabilizing coating for the inverted nano-core (iNC). Hydroxypropyl methylcellulose acetate-succinate polymer (HPMCAS 126), chitosan and polyethylene glycol (PEG) polymers were used in the second precipitation step to generate anionic, cationic and neutral NPs, respectively.

**Materials.**

Soybean trypsin inhibitor (SBTI) and zinc chloride were purchased from Sigma Aldrich. Insulin-Zn was supplied by Eli Lilly and Company. Polystyrene-block-polyacrylic acid (PS<sub>5k</sub>-b-PAA<sub>4.8k</sub>) polystyrene-block-polyethylene glycol (PS<sub>1.6k</sub>-b-PEG<sub>5k</sub>) was purchased from Polymer Source (Dorval Canada). The non-degradable block copolymer was chosen to achieve particle formation without involving polymer hydrolysis, as would occur for polylactide-based polymers. However, we have shown that self-assembly works equally well with biodegradable polymers.[18, 23] HPMCAS 126 was supplied by Dow Chemical Company. Chitosan (90%+ deacetylated) was purchased from Spectrum Chemicals (New Brunswick, NJ). All solvents were purchased from Fisher Scientific.

**Inverse Flash NanoPrecipitation (iFNP).**

iFNP was performed using a confined impinging jet mixer (CIJ) by rapidly mixing a solvent stream (95% DMSO, 5% water) with an antisolvent (DCM) stream. The operation and design of the mixer have been described previously.[17] Two syringes were used to inject 500 µL of the solvent and 500 µL of antisolvent through the mixer. When using the four-jet multiple inlet vortex mixer (MIVM) mixer, four 500 µL syringes were used. The solvent stream contained PS<sub>5k</sub>-b-PAA<sub>4.8k</sub> and insulin and/or SBTI at desire ratios. For example, an iFNP experiment encapsulating insulin and SBTI was carried out as follows. PS-b-PAA and insulin were dissolved separately in DMSO. SBTI was dissolved in water at 20× of the desired final concentration. Polymer and peptides were mixed and diluted with DMSO such that the final solvent mixture contained 95% DMSO and 5% water with final concentrations of 5 mg/mL PS-b-PAA, 4 mg/mL SBTI, and 1 mg/mL insulin. In experiments with only insulin or SBTI, the remaining volume was made up with water or DMSO. Zinc chloride was dissolved in methanol and added to the DCM solvent stream affording a 1:1 charge ratio accounting for the total negative charge contributed by PS-b-PAA. Typically, 0.5 mL of solvent stream was impinged against 0.5 mL of antisolvent using a CIJ mixer and diluted into a reservoir of 4.5 mL of additional antisolvent.

**Extraction of DMSO and Transfer of Inverse Nano-Cores (iNCs) from DCM to Water-Miscible Solvents.**

DMSO was extracted from the iNC dispersion after iFNP. To 5 mL of iNCs, 3 mL of either brine (13% w/w NaCl) or 1× phosphate-buffered saline (PBS) was added, and the mixtures were gently shaken on a tabletop shaker for 30 minutes. Samples were transferred to 15 mL conical tubes and centrifuged using a bucket rotor at 2000 RCF for 5 minutes at room temperature. The bottom DCM
phase was carefully transferred and iNC sizes after DLS-determined DMSO extraction. iNCs were transferred from DCM to a water-miscible solvent by repeated rounds of concentration and dilution. 4 mL of tetrahydrofuran (THF) or acetone was added to 5 mL of extracted iNCs. This iNC suspension was concentrated by rotary evaporation to 1 mL. Seven mL of THF or acetone was then added, and the mixture was again concentrated to 1 mL. Two additional rounds of dilution and concentration were performed, leading to a final suspension of iNCs in 1 mL of THF or acetone.

**FNP of iNCs with HPMCAS 126, chitosan, or PEG.**

iNCs were coated with HPMCAS, chitosan, or PEG by FNP. For all experiments, the mass ratio of coating polymer to iNCs was kept constant at 1.5:1. The coating polymers and mixing conditions for each are described in the Results and Discussion section. The coating polymer was first dissolved in THF and added to concentrated iNCs in THF. This mixture was impinged against water at a 1:1 volume ratio in a CIJ mixer and immediately diluted 9x further in water.

**Encapsulation Assays.**

Encapsulation efficiency (EE) and release were evaluated by high-performance liquid chromatography (HPLC). After the second coating was added by FNP and THF, for EE measurements, samples were removed under vacuum and were passed through a wetted 100 kDa Amicon® filter. The filtrate was lyophilized and resuspended in 1/10 its original volume for better detection on HPLC. Standard curves for insulin and SBTI (provided in Supplemental Information (SI) were developed with UV−vis spectrometer at 210 nm. The unencapsulated insulin and SBTI was less than 10% of the amount loaded in all samples, meaning that the EE was 90+. With the non-degradable PS-b-PEG polymer used for the initial iFNP step, it was impossible to solubilize and release the iNC components to measure EE on the iNC directly.

1. **iFNP to encapsulate insulin and SBTI**

2. **Encapsulating C10 and Coating by FNP**

---

**Figure 2. General Scheme for Encapsulation of Insulin, SBTI, and C10 into Nanoparticles**

1. Inverse Flash Nano-Precipitation (iFNP) to encapsulate insulin and SBTI.
2. Flash Nano-precipitation (FNP) to encapsulate C10 and coat with HPMCAS, chitosan, or polyethylene glycol (PEG)
Dynamic Light Scattering (DLS) and Zeta Potential.

Particle size and zeta potential measurements were taken using a Malvern Nano ZS equilibrated at 25°C. For DLS measurements, samples were diluted 10-fold in a matching solvent and measured at a scattering angle of 173 degrees with a 632 nm helium-neon laser. The reported sizes shown were the mean of three measurements of 10 runs each. Reported Z-average diameters are the intensity-weighted diameters obtained from DLS measurements, and PDI is the polydispersity index obtained from the cumulants fitting program and reported by the DLS instrument. For zeta potential measurements, samples were diluted with 1× PBS, to a final concentration of 0.1× PBS. Zeta potential measurements were carried out using zeta potential mode and the Smoluchowski model. The detailed size and PDI results of nanoparticles could be found in SI.

Results and Discussion

The overall processes involved in the study are schematically shown in Figure 2.

Encapsulation of SBTI and Insulin by Inverse Flash Nano-precipitation (iFNP):

In the first step, the insulin and SBTI were encapsulated using iFNP. The term “inverse” denotes that a water-soluble species is being precipitated into an organic phase, in contrast to the normal FNP that involves precipitating hydrophobic species into water[12, 24, 25]. The principles of operation of the mixers using in FNP and iFNP processing Cij have been described previously.[13-15] SBTI, insulin, and PS-b-PAA were solubilized in DI water and DMSO with a final solution comprising 95% DMSO/5% water. The optimal ratio of insulin to SBTI had been selected as 1:4 by mass. This solution was then micro-mixed against a solution of ZnCl₂ in DCM as anisolvant using a CIJ mixer. The Zn²⁺ ionically crosslinked the block copolymer's free carboxylic group and stabilized the inverted nano-cores (iNCs) for the subsequent coating step. iFNP produced PS-PAA iNCs of 49±2 nm for the insulin alone, 74±2 nm for SBTI alone, and 82±2 nm for the combined insulin and SBTI, as shown in Figure 3B. In the first iFNP step, the combined insulin and SBTI iNCs comprised 50 wt% protein. The strength of crosslinking was evaluated by testing the swelling of the NCs in 90% DMSO, with the retention of iNC size indicating substantial crosslinking, as shown in Figure 1C. Without Zn²⁺ as the crosslinker, iNCs dissolved in DMSO (data not shown).

Figure 3: Encapsulation of insulin and SBTI by iFNP. A) Schematic of the iFNP process used to encapsulate insulin and SBTI. B) iNC size distribution by DLS of PS-PAA/insulin (49nm), PS-PAA/SBTI (74nm), and PS-PAA/insulin/SBTI (82nm) produced by iFNP. The detailed size and PDI results are provided in SI.
Transferring iNCs into Water-Miscible Solvent and Extraction of DMSO.

The iNCs made with PS-PAA/insulin/SBTI in DCM were first extracted to remove DMSO and then transferred into a water-miscible solvent to enable the next FNP coating step. Comparing size distributions before and after extraction in Figure 4A demonstrated that the iNC remained at its initial size after extraction of DMSO by either NaCl or PBS.

To transfer the iNCs to a water-miscible solvent for the second coating step, iNCs were solvent swapped into THF or acetone using a rotary evaporator. Figure 4B shows that after swapping into THF, iNCs size distribution remained the same as before solvent swapping. When swapped into acetone, the iNCs average size increased from 105 nm to a few μm due to particle aggregation in this solvent. This indicated that the PS steric stabilizing coating on the iNCs were not sufficiently soluble in acetone; consequently, the iNCs aggregated. All further experiments were conducted in THF.

Anionic Surface Functionalization: HPMCAS.

The NCs, now in a water-miscible organic solvent, must be coated with a biocompatible surface stabilizer and transferred into an aqueous phase. This is accomplished with a second FNP step. iNCs were covered with HPMCAS, where the carboxylic acids provide the anionic charge, as shown in Figure 4. HPMCAS at a 1.5 mass equivalents (relative to iNCs mass) was mixed with iNCs in THF. This mixture was flash precipitated against water using a CIJ mixer and immediately diluted 9× with water. NCs size distributions are shown in Figure 5B.

The initial iNC diameter was 214 nm, upon coating the final nanoparticles (NPs) size were 322 nm. The increase in size is consistent with a diffuse HPMCAS surface layer of 54 nm. It is known that HPMCAS creates gels that slowly hydrate and erode in sustained-release tablets. Therefore, it was surprising that during the rapid FNP precipitation process, the hydrophobic acetyl groups anchor on the hydrophobic NC surface, and the carboxylic acid groups orient into the solvent phase to form colloidal stable NPs, rather than aggregated gels. The electrostatic repulsions between particles prevent aggregation and creates the stabilized NPs shown in Figure 5.
Cationic Surface Functionalization: Chitosan:

Two chitosan formulations were used to deposit the cationic chitosan on the iNC surfaces using FNP. In each case, the chitosan was introduced in the aqueous phase, and the iNCs were introduced in the THF phase. The difference was the cationic charge on the chitosan. In the first case, chitosan was dissolved in 1% aqueous acetic acid to ionize the amine groups and mixed with a CIJ mixer against iNCs in THF. The dispersion was immediately diluted with 9x water by volume. The NCs aggregated to ~1 micron. The acetic acid did not sufficiently ionize the chitosan to produce electrostatic repulsions strong enough to prevent aggregation. In contrast, when chitosan was isolated from a strong acid solution as an amine:HCl and the chitosan:HCl was dissolved in water and put through the same FNP process, 321 nm stable NPs were produced. The DLS data in Figure 6B shows that the chitosan layer was 80 nm thick, indicating a diffuse steric layer on the NCs surface.

| Components     | Size (nm)   | PDI  |
|----------------|-------------|------|
| iNCs/HPMCAS    | 322 ± 6     | 0.18 |
| iNCs alone     | 214 ± 5     | 0.27 |

Figure 5: iNC Coating with HPMCAS. (A) iNCs swapped into THF were coated with HPMCAS 126G in a second FNP step. (B) The initial size distributions of the iNCs in DCM and the HPMCAS coated iNCs are shown.

Figure 6: Coating iNCs with chitosan-HCl. (A) Schematic of FNP process, (B) DLS data on initial iNCs in DCM and final size distribution after chitosan surface functionalization.
Neutral Surface Functionalization: PEG:

For a neutral surface, PS$_{1.6k}$-b-PEG$_{5k}$ was deposited using FNP. PS-b-PEG was added to the iNCs in THF and flashed against an equal volume of water, followed by immediate dilution in 9x water. The resulting NPs were 172 nm in size. The DLS data in Figure 7 shows a small PS-b-PEG micelle peak at ~30 nm and then a prominent NP peak.

| Components          | Size (nm) | PDI |
|---------------------|-----------|-----|
| iNCs, PS-b-PEG      | 172 ± 8   | 0.56|
| iNCs alone          | 88 ± 4    | 0.19|

Figure 7. iNC Coating with PS-b-PEG. (A) iNCs swapped into THF were coated with PS-b-PEG in a second FNP step. (B) The size distributions of the iNCs in DCM, transferred to THF, and coated with PS-b-PEG are shown. The sizes increase upon coating with the PS-b-PEG layer to 172 nm.

The increase in size by 84 nm is larger than expected for the PS-b-PEG layer alone, which should increase in size approximately equal to that of the micelle size (i.e., ~30 nm). Micelles of this size can be readily removed from the large NP population by ultrafiltration. The PS-b-PEG corona size has been studied and modeled by Pagels.[23] The increase in size might result from some loss of stability, and limited aggregation, as some of the stabilizing polymer is lost due to micellization.

Incorporation of Caprate (C10) Permeabilizing Agent:

The formulation's final element requires co-encapsulation of sodium caprate (C10) in the NPs with the insulin/STBI. The mass ratio of caprate to insulin was chosen to be 4:1 in all of the NC formulations. Different mechanisms are required to incorporate the caprate in the anionic HPMCAS NCs, the cationic chitosan NCs, and the neutral PS-b-PEG NCs. The HPMCAS polymer is significantly hydrophobic and will bind with hydrophobic compounds. We transformed the anionic caprate into a hydrophobic complex by combining it with ZnCl$_2$. FNP was performed with sodium caprate dissolved in water impinged against HPMCAS, iNCs, and ZnCl$_2$. ZnCl$_2$ interacts ionically with C10 to form a hydrophobic ZnC$_{10}$ complex that can be incorporated into the hydrophobic layer of the HPMCAS coated iNCs. The ratio of C10 to ZnCl$_2$ was chosen as 2:1 on a charge equivalent basis.
Figure 8: Coating with HPMCAS and sodium caprate (C10) permeation enhancer. To incorporate C10 into the hydrophobic layer of HPMCAS-coated NPs, FNP was performed with sodium caprate dissolved in water impinged against HPMCAS, iNCs, and ZnCl2. The initial 214 nm size is increased to 486 nm by the C10 inclusion.

Figure 8 shows the iNC coated with HPMCAS alone, which produced NCs of 223 nm. When C10:ZnCl2 was added to the formulation, the resulting NCs were 486 nm. There is a main peak and a smaller peak at ~100nm, which may be C10 encapsulated by hydroxypropyl methylcellulose acetate succinate (HMPCAS) without the core. We have observed previously the formation of larger "coated" nanoparticles that include some of the smaller hydrophobic species and a population of smaller nanoparticles comprising only the smaller hydrophobic species.[26].

![Figure 8: Coating with HPMCAS and sodium caprate (C10) permeation enhancer.](image)

| Components           | Sizes (nm) | PDI  |
|----------------------|------------|------|
| iNCs/HPMCAS/Zn/C10  | 486 ± 60   | 0.40 |
| iNCs/HPMCAS         | 322 ± 6    | 0.18 |
| iNCs alone          | 214 ± 5    | 0.27 |

Fig. 9. Caprate is complexed with the cationic chitosan NCs via charge interactions. The narrow size distribution at 206 nm indicates successful high loading with the caprate.

![Figure 9: Caprate is complexed with the cationic chitosan NCs via charge interactions.](image)

| Components                  | Size (nm) | PDI  |
|-----------------------------|-----------|------|
| iNCs, C10, Chitosan.HCl     | 206 ± 7   | 0.15 |
| iNCs, Chitosan.HCl          | 143 ± 1   | 0.17 |
| iNCs alone                  | 96.7 ± 0.7| 0.148|

718
In the desired oral application, the delivery of caprate via the 100 nm nanoparticles may be advantageous. The size difference between the 486 nm coated nanoparticles, and the 100 nm nanoparticles would make a centrifugal separation straightforward.

The chitosan NCs do not require the Zn salt formation since the anionic caprate can complex with the cationic groups on chitosan (see supplementary Figure S4). The scheme in Figure 9 depicts coating of iNCs with chitosan complexed to C10. To allow complexation of C10 and chitosan to coincide with chitosan interaction with iNCs, a MIVM was used with sodium caprate dissolved in water in one stream, chitosan-HCl dissolved in water in a second stream, a third stream of water, and a fourth stream of iNCs in THF. If the chitosan and sodium caprate were added to the same aqueous stream, they precipitate and no longer interact with the iNCs in the THF stream. This is an example of the MIVM mixer's flexibility, enabling the assembly of more complex NC formulations. As shown in Figure 9, without C10, the NPs were 143 nm, and with C10 encapsulation, the size increased to 206 nm, demonstrating the co-loading of the C10 into the final NPs. The zeta potential of the chitosan-coated iNCs with C10 was +8 mV (SI Figure S5). The zeta potential of chitosan-coated NCs without C10 is +30 mV, and our previous work on PEG-coated iNCs showed zeta potentials in the range −2 mV - −12 mV.[18]

C10 was incorporated into the PS-b-PEG formulation similarly as with the HPMCAS-coating; that is, the hydrophobicity of the C10:ZnCl2 was exploited to co-precipitate the complex with the PS hydrophobic blocks of the steric stabilizing polymer.

As shown in Figure 10, the NPs size was 360 nm, with a smaller peak at 78 nm. The smaller peak is consistent with block copolymer encapsulation of the C10: ZnCl2 into some NPs, which do not contain the insulin/SBTI cores.

### Table 1

| Components                  | Sizes (nm) | PDI  |
|-----------------------------|------------|------|
| iNCs/PS-b-PEG/C10/ZnCl2     | 362 ± 77   | 0.48 |
| iNCs/PS-b-PEG               | 172 ± 8    | 0.56 |
| iNCs alone                  | 88 ± 4     | 0.19 |

Figure 10. Coating with PS-b-PEG and caprate permeabilizer. To incorporate the C10 into the hydrophobic layer of PS-b-PEG-coated iNCs, FNP was performed with C10 dissolved in water impinged against PS-b-PEG, iNCs, and ZnCl2. The initial 88 nm size is increased to 362 nm with the caprate inclusion, with a second smaller population observed at 78 nm. The summary of the formulation conditions for the initial inverse nanocarrier core (iNC) and the finally formulated NC are show in Table 1 and 2, respectively.
Table 1. Formulation conditions for preparation of the initial inverse nanocarriers, iNC.

| Inverse Nanocarrier Formulation (iFNC) | Stream 1 in CIJ mixer (polar phase with actives: 95vol% DMSO, 5 vol% DI Water) | Stream 2 in CIJ mixer (antisolvent phase: methylene chloride) |
|----------------------------------------|--------------------------------------------------------------------------------|---------------------------------------------------------------|
|                                        | Concentration | Mass in 500 µL injection | Concentration | Mass in 500 µL injection |
| Insulin                                | 1 mg/mL       | 0.5 mg                  |              |                          |
| Soybean trypsin inhibitor (SBTI)       | 4 mg/mL       | 2.0 mg                  |              |                          |
| PS-b-PAA polymer stabilizer            | 5 mg/mL       | 2.5 mg                  |              |                          |
| ZnCl₂ crosslinker                      |                |                         | 4.62 mg/mL   | 2.31 mg                  |

1 mL iFNC from mixer is diluted into 4.5 mL methylene chloride.

Table 2. Formulation for the final coated nanocarriers.

| Coating Formulation | Stream 1 (THF) | Stream 2 (Aqueous antisolvent) | Stream 3 in MIVM mixer (Aqueous antisolvent) | Stream 4 in MIVM mixer (Aqueous antisolvent) |
|---------------------|-----------------|-------------------------------|-----------------------------------------------|-----------------------------------------------|
|                     | Concentration   | Mass in 500 µL injection      | Concentration | Mass in 500 µL injection | Concentration | Mass in 500 µL injection |
| HPMCAS 126          | iNC: 10 mg/mL   | 5 mg                          | NaC10: 4 mg/mL | 2 mg                       |              |                          |
|                     | HPMCAS: 15 mg/mL | 7.5 mg                        |                |                            |              |                          |
|                     | ZnCl₂: 2.8 mg/mL | 1.4 mg                        |                |                            |              |                          |
| Chitosan            | iNC: 10 mg/mL   | 5 mg                          | NaC1: 4.0 mg/mL | 2 mg                       | Chitosan: 15 mg/mL | 7.5 mg                  |
|                     |                 |                               |                |                            |              | 500 µL DI water          |
| PEG-b-PS            | iNC: 10 mg/ml   | 5 mg                          | NaC10: 4 mg/mL | 2 mg                       |              |                          |
|                     | PEG-b-PS: 15 mg/mL | 7.5 mg                        |                |                            |              |                          |
|                     | ZnCl₂: 2.8 mg/mL | 1.4 mg                        |                |                            |              |                          |

1 mL iFNC from mixer is diluted into 9 mL DI water for two stream operation.
Inverse nanocarriers (iNCs) are given three separate polymer coatings to prepare negative NCs (HMCAS), cationic (chitosan), and neutral (PEG) surfaces. For those formulations containing the permeabilization enhancer sodium caprate (NaC10) the compositions are presented. For formulations not containing NaC10 that component was omitted. The HPMCAS and PEG-b-PS coating were applied in a two-stream CIJ mixer and the compositions of those streams are shown. For the HPMCAS and PEG coatings, ZnCl₂ was incorporated to precipitate the NaC10 onto the iNC surface. For the chitosan surface, the electrostatic interaction between the chitosan and NaC10 was used to incorporate the C10. For chitosan coating, the four-stream MIVM was used to prevent the chitosan interaction with the negatively charged C10 before mixing.

Conclusions

The results presented show the successful preparation of highly loaded NPs with insulin, trypsin inhibitor, and permeation enhancer. The NPs have been produced by a scalable, facile process involving two precipitation steps using the FNP technology. NPs prepared by this two-step iFNP process demonstrate the feasibility of generating highly loaded nanoparticles encapsulating a mixture of API and functional excipients. We have shown the ability to formulate nanoparticles containing dual protein cores and a hydrophobic excipient (the permeabilization agent, caprate). The flexibility of the processing enables the application of anionic, cationic and neutral surface coatings. In this proof-of-principle study, iNCs were developed using PS-b-PAA, which is a non-degradable polymer. To enable this successful clinical translation of these NPs, biodegradable block copolymers such as polyaspartic acid-b-polylactic acid (PAsp-b-PLA) can be used in the 1st precipitation step to generate the nano-cores.[17] Further, optimization of polymer composition provides an opportunity for controlling the release kinetics of the API and associated excipients.

It is important to note that the iFNP process can be easily interfaced with spray drying or lyophilization to isolate the formulated particles as solids for oral solid dosage formulations. We have demonstrated drying and redispersion to nanoparticle form for similar FNP formulations.[27-29] This study was directed towards addressing challenges in oral peptide delivery; however, these particles also offer interesting opportunities for parenteral administration.

Acknowledgment

We would like to thank Eli Lilly and Company for financial support of this research.

Quote this article as: McManus SA, Zhang YG, Kim B, Lee BK, ElSayed MEH, Prud’homme RK, Co-encapsulation by Flash NanoPrecipitation of Insulin, Trypsin Inhibitor and Caprate Permeabilization Enhancer for Oral Administration, Precis. Nanomed. 2020 December;3(5):710-72, https://doi.org/10.33218/001c.xxxxx

References

[1] H. A. D. Lagassé et al., "Recent advances in (therapeutic protein) drug development," (in Eng), F1000Research, vol. 6, pp. 113-113, 2017.
[2] B. J. Bruno, G. D. Miller, and C. S. Lim, "Basics and recent advances in peptide and protein drug delivery," (in eng), Therapeutic delivery, vol. 4, no. 11, pp. 1443-1467, 2013.
[3] A. Muheem et al., "A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives," Saudi Pharmaceutical Journal, vol. 24, no. 4, pp. 413-428, 2016/07/01/ 2016.
[4] P. M. Anderson, D. C. Hanson, D. E. Hasz, M. R. Halet, B. R. Blazar, and A. C. Ochoa, "Cytokines in liposomes: Preliminary studies with IL-1, IL-2, IL-6, GM-CSF and interferon-γ," Cytokine, vol. 6, no. 1, pp. 92-101, 1994.
[5] A. Weiner, "Liposomes for Protein Delivery: Selecting Manufacturing and Development Processes," Immunomethods, vol. 4, pp. 201-209, 1994.

[6] M. Diwan and T. G. Park, "Pegylation enhances protein stability during encapsulation in PLGA microspheres," Journal of Controlled Release, vol. 73, no. 2-3, pp. 233-244, 2001.

[7] S. E. Paramonov et al., "Fully Acid-Degradable Biocompatible Polyacetal Microparticles for Drug Delivery," Bioconjugate Chemistry, vol. 19, no. 4, pp. 911-919, 2008.

[8] N. Murthy, M. Xu, S. Schuck, J. Kunisawa, N. Shastri, and J. M. Frechet, "A macromolecular delivery vehicle for protein-based vaccines: Acid-degradable protein-loaded microgels," Proceedings of the National Academy of Sciences, vol. 100, no. 9, pp. 4995-5000, 2003.

[9] S. Allen, O. Osorio, Y. G. Liu, and E. Scott, "Facile assembly and loading of theranostic polymericosomes via multi-impingement flash nanoprecipitation," Journal of Controlled Release, vol. 262, no. March, pp. 91-103, 2017.

[10] U. Bilati, E. Allémann, and E. Doelker, "Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles," European Journal of Pharmaceutical Sciences, vol. 24, no. 1, pp. 67-75, 2005.

[11] U. Bilati and E. Doelker, "Nanoprecipitation Versus Emulsion-based Techniques for the Encapsulation of Proteins Into Biodegradable Nanoparticles and Process-related Stability Issues," AAPS PharmSciTech, vol. 6, no. 4, pp. 594-604, 2005.

[12] R. F. Pagels and R. K. Prud'homme, "Polymeric nanoparticles and microparticles for the delivery of peptides, biologics, and soluble therapeutics," Journal of Controlled Release, vol. 219, no. Supplement C, pp. 519-535, 2015/12/10/ 2015.

[13] C. E. Markwalter and R. K. Prud'homme, "Design of a Small-Scale Multi-Inlet Vortex Mixer for Scalable Nanoparticle Production and Application to the Encapsulation of Biologics by Inverse Flash NanoPrecipitation," Journal of pharmaceutical sciences, 2018.

[14] Y. Liu, C. Y. Cheng, R. K. Prud'homme, and R. O. Fox, "Mixing in a multi-inlet vortex mixer (MIVM) for flash nano-precipitation," Chemical Engineering Science, vol. 63, no. 11, pp. 2829-2842, Jun 2008.

[15] B. K. Johnson and R. K. Prud'homme, "Chemical processing and micromixing in confined impinging jets," AIChE Journal, vol. 49, no. 9, pp. 2264-2282, 2003.

[16] J. Feng, C. E. Markwalter, C. Tian, M. Armstrong, and R. K. Prud'homme, "Translational formulation of nanoparticle therapeutics from laboratory discovery to clinical scale," Journal of translational medicine, vol. 17, no. 1, p. 200, 2019.

[17] C. E. Markwalter, R. F. Pagels, B. K. Wilson, K. D. Ristroph, and R. K. Prud'homme, "Flash nanoprecipitation for the encapsulation of hydrophobic and hydrophilic compounds in polymeric nanoparticles," JoVE (Journal of Visualized Experiments), no. 143, p. e58757, 2019.

[18] C. E. Markwalter, R. F. Pagels, A. N. Hejazi, A. G. R. Gordon, A. I. Thompson, and R. K. Prud'homme, "Polymeric nanocarrier formulations of biologics using inverse Flash NanoPrecipitation," AAPS Journal, vol. 22, no. 18, 2020.

[19] A. Alexander, S. Ajazuddin, D. Tripathi, T. Verma, J. Mayura, and S. Patel, "Mechanism responsible for mucoadhesion of mucoadhesive drug delivery system: a review," International journal of applied biology and pharmaceutical technology, vol. 2, no. 1, pp. 434-445, 2011.

[20] B. M. Boddupalli, Z. N. Mohammed, R. A. Nath, and D. Banji, "Mucoadhesive drug delivery system: An overview," Journal of advanced pharmaceutical technology & research, vol. 1, no. 4, p. 381, 2010.

[21] M. Yang et al., "Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus," Angewandte Chemie, vol. 123, no. 11, pp. 2645-2648, 2011.
[22] L. M. Ensign, C. Schneider, J. S. Suk, R. Cone, and J. Hanes, "Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery," Advanced Materials, vol. 24, no. 28, pp. 3887-3894, 2012.

[23] R. F. Pagels, J. Edelstein, C. Tang, and R. K. Prud'homme, "Controlling and Predicting Nanoparticle Formation by Block Copolymer Directed Rapid Precipitations," Nano Letters, vol. 18, no. 2, pp. 1139-1144, Feb 2018.

[24] R. F. Pagels and R. K. Prud'homme, "Inverse Flash NanoPrecipitation for Biologics Encapsulation: Nanoparticle Formation and Ionic Stabilization in Organic Solvents," in Control of Amphiphile Self-Assembling at the Molecular Level: Supra-Molecular Assemblies with Tuned Physicochemical Properties for Delivery Applications, vol. 1271(ACS Symposium Series, no. 1271): American Chemical Society, 2017, pp. 249-274.

[25] C. E. Markwalter and R. K. Prud'homme, "Inverse Flash NanoPrecipitation for Biologics Encapsulation: Understanding Process Losses via an Extraction Protocol," in Control of Amphiphile Self-Assembling at the Molecular Level: Supra-Molecular Assemblies with Tuned Physicochemical Properties for Delivery Applications, vol. 1271(ACS Symposium Series, no. 1271): American Chemical Society, 2017, pp. 275-276.

[26] N. M. Pinkerton et al., "Single-Step Assembly of Multimodal Imaging Nanocarriers: MRI and Long-Wavelength Fluorescence Imaging," Advanced healthcare materials, vol. 4, no. 9, pp. 1376-1385, 2015.

[27] J. Feng, C. E. Markwalter, C. Tian, M. Armstrong, and R. K. Prud'homme, "Translational formulation of nanoparticle therapeutics from laboratory discovery to clinical scale," Journal of Translational Medicine, vol. 17, Jun 2019, Art. no. 200.

[28] J. Feng et al., "Amorphous nanoparticles by self-assembly: processing for controlled release of hydrophobic molecules," Soft matter, vol. 15, no. 11, pp. 2400-2410, 2019.

[29] J. Feng et al., "Rapid Recovery of Cofazimine-Loaded Nanoparticles with Long-Term Storage Stability as Anti-Cryptosporidium Therapy," ACS applied nano materials, vol. 1, no. 5, pp. 2184-2194, 2018 May 25 (Epub 2018 Apr 2018).
**Supporting Information**

**Table S1**: NC size and PDI for Figure 1B

| Name  | Size (nm) | PDI |
|-------|-----------|-----|
| NC1   | 48.6 ± 2.1| 0.2 |
| NC2   | 73.9 ± 1.5| 9   |
| NC3   | 81.7 ± 1.7| 9   |

**Table S2**: NC size and PDI for Figure 1C

| Name  | Size (nm) | PDI |
|-------|-----------|-----|
| NC1   | 149.5 ± 94.1| 0.4 |
| NC2   | 77.4 ± 15.6| 0.3 |
| NC3   | 75.8 ± 8.2 | 0   |

**Table S3**: NC size and PDI for Figure 2

| Process               | Size (nm) | PDI  |
|-----------------------|-----------|------|
| Extract with brine    | 120.3 ± 3.2 | 0.13 |
| Extract with PBS      | 115.7 ± 2.2 | 0.13 |
| Solvent swap with THF | 129.4 ± 3.0 | 0.16 |
| Solvent swap with acetone | 1275.7 ± 202 | 0.60 |

**Table S4**: NC size and PDI for Figure 3

| Components            | Size (nm) | PDI  |
|-----------------------|-----------|------|
| iNCs in THF           | 134.2 ± 4.0 | 0.16 |
| iNCs/HPMCA S          | 321.9 ± 5.9 | 0.18 |
| HPMCAS only           | 222.9 ± 7.9 | 0.17 |
| iNCs only             | 214.1 ± 4.8 | 0.27 |
Figure S1: Standard Curves for (A) SBTI and (B) insulin from integration of the main peaks on HPLC.

1. iFNP to encapsulate insulin and SBTI

2. Encapsulating C10 and Coating by FNP

Figure S2: Encapsulation of insulin, SBTI, and sodium caprate into NCs. 1. Inverse Flash NanoPrecipitation (iFNP) to encapsulate insulin, and SBTI. 2. Flash NanoPrecipitation (FNP) to encapsulate sodium caprate and coat with HPMCAS, chitosan, or PS-b-PEG.
**Figure S3**: Coating iNCs with chitosan and chitosan-HCl. (A) chitosan coated from a 1% acetic acid and chitosan NCs showed significant aggregation. (B) The more highly charged, chitosan-HCl produced cationic, chitosan coated NCs in FNP process.

**Table S5.** NC size and PDI for Figure S3A.

| Components          | Sizes (nm)  | PDI  |
|---------------------|-------------|------|
| iNCs/THF            | 132.7 ± 1.0 | 0.16 |
| iNCs/chitosan       | 1254 ± 192  | 0.56 |
| chitosan only       | 491.6 ±     | 0.25 |
| iNPs only           | 93.6        | 0.27 |
Table S6: NC size and PDI for Figure S3B.

| Components       | Size (nm)   | PDI |
|------------------|-------------|-----|
| iNCs/Chitosan-HCl| 320.7 ± 16.6| 0.28|
| iNCs only        | 160.5 ± 4.0 | 0.27|
| iNCs/THF         | 87.1 ± 4.3  | 0.28|

**Figure S4**: iNC coating with PS-b-PEG. (A) iNCs swapped into THF were coated with PS-b-PEG in a second FNP step. (B) The size distributions of the iNCs in DCM, transferred to THF, and coated with PS-b-PEG are shown.

Table S7. NC size and PDI for Figure S4B

| Components               | Size (nm)   | PDI  |
|--------------------------|-------------|------|
| iNCs in DCM              | 87.6 ± 4.0  | 0.19 |
| iNCs in THF              | 81.2 ± 7.7  | 0.21 |
| iNCs, PS-b-PEG           | 171.9 ± 7.7 | 0.56 |
Figure S5: Figure S4: DLS and zeta potential of chitosan:NaC10 coated iNCs and uncoated iNCs (MIVM against 3 streams of water). Both particles give similar size distributions. Uncoated NCs gave a negative zeta potential, (-30 mV) associated with some exposure of the inner acrylic acid polymer block on the iNC surface, since a second coating layer of polymer was not applied. The chitosan:NaC10 coated NCs gave a positive zeta potential (+8 mV). While some of the chitosan cationic groups were involved in complexing the anionic C10 acid, sufficient cationic charge was available to give the iNCs a cationic charge.